Multicentre, Open Label, Prospective, Randomised Clinical Trial of an Antiretroviral Simplification Treatment With Efavirenz + Abacavir + 3TC [lamivudine] Once Daily
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2010
At a glance
- Drugs Efavirenz (Primary) ; Lamivudine/abacavir (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications HIV infections; HIV-1 infections
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 Jan 2010 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
- 09 Nov 2008 48-week results were presented at the 9th International Congress on Drug Therapy in HIV Infection.